Vimian Group AB
STO:VIMIAN
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
20.0822
45.4
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one VIMIAN stock under the Base Case scenario is 46.2 SEK. Compared to the current market price of 43.7 SEK, Vimian Group AB is Undervalued by 5%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Vimian Group AB
Run backtest to discover the historical profit from buying and selling VIMIAN based on its intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Price Target |
Loading
|
Revenue Forecast |
|
Operating Income Forecast |
|
Earnings Forecast |
|
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Vimian Group AB
Balance Sheet Decomposition
Vimian Group AB
Current Assets | 190.4m |
Cash & Short-Term Investments | 41.2m |
Receivables | 73.2m |
Other Current Assets | 75.9m |
Non-Current Assets | 806.2m |
Long-Term Investments | 49.1m |
PP&E | 36.5m |
Intangibles | 718.5m |
Other Non-Current Assets | 2.1m |
Current Liabilities | 94.8m |
Accounts Payable | 25.7m |
Accrued Liabilities | 15.8m |
Other Current Liabilities | 53.3m |
Non-Current Liabilities | 225.5m |
Long-Term Debt | 178.6m |
Other Non-Current Liabilities | 46.9m |
Earnings Waterfall
Vimian Group AB
Revenue
|
344.6m
EUR
|
Cost of Revenue
|
-182m
EUR
|
Gross Profit
|
162.6m
EUR
|
Operating Expenses
|
-123.4m
EUR
|
Operating Income
|
39.2m
EUR
|
Other Expenses
|
-29.4m
EUR
|
Net Income
|
9.8m
EUR
|
Free Cash Flow Analysis
Vimian Group AB
EUR | |
Free Cash Flow | EUR |
Vimian Group reported a strong second quarter with 11% organic growth, driven by its three main segments. Specialty Pharma saw 13% growth, while MedTech posted 10%, despite a slowdown in the U.S. surgical market. Veterinary Services grew by 18%, recruiting 400 new member clinics. Adjusted EBITA margin improved from 25% to 27.2%. The company's leverage is reduced to 1.4x, enabling further acquisitions. Vimian remains optimistic about achieving high single-digit organic growth for the full year, except for diagnostics, which faced a 9% revenue decline.
What is Earnings Call?
VIMIAN Profitability Score
Profitability Due Diligence
Vimian Group AB's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
Vimian Group AB's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
VIMIAN Solvency Score
Solvency Due Diligence
Vimian Group AB's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Score
Vimian Group AB's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VIMIAN Price Targets Summary
Vimian Group AB
According to Wall Street analysts, the average 1-year price target for VIMIAN is 44.17 SEK with a low forecast of 28.28 SEK and a high forecast of 61.95 SEK.
Shareholder Yield
Current shareholder yield for VIMIAN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
VIMIAN Price
Vimian Group AB
Average Annual Return | -32.89% |
Standard Deviation of Annual Returns | 45.82% |
Max Drawdown | -83% |
Market Capitalization | 22.5B SEK |
Shares Outstanding | 517 032 000 |
Percentage of Shares Shorted |
N/A
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Vimian Group AB operates as an animal health company. The company is headquartered in Stockholm, Stockholm and currently employs 1,068 full-time employees. The company went IPO on 2021-06-18. The firm is a parent company of the group of companies operating with a purpose of improving animal health through science and technology. The Group delivers solutions to veterinary professionals, labs and pet parents around the world. The purpose of Vimian Group is to unite companies in selected niches of animal health and help them grow faster. The firm invests in innovation and new technologies to advance veterinary medicine. The Group covers four essential and rapidly evolving areas within animal health: Specialty Pharma, Diagnostics, Veterinary Services and MedTech. Vimian provides individual businesses with access to its networks, advisory services, infrastructure and capital.
Officers
The intrinsic value of one VIMIAN stock under the Base Case scenario is 46.2 SEK.
Compared to the current market price of 43.7 SEK, Vimian Group AB is Undervalued by 5%.